← brief for 2026-10-14 · Slowing decline

SGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis.

Article D Peer reviewed Preclinical

Key takeaways

This study compared two diabetes drugs that also protect the heart and kidneys. It found that one drug, sotagliflozin, reduced blood clotting in the test tube. The other drug, empagliflozin, did not. This was a lab study, not in people yet. It may explain why one drug has extra heart benefits.

Who did this work

Stanger L · Goerger K · Zhang X · Yalavarthi P · Rickenberg A · Yamaguchi A · Flores Nascimento M · Kilgore A · Kim H · Wu X · Guo Y · Dahlgren AR

Source

Article · PubMed, the drug frontier · 2026 Oct 13
https://pubmed.ncbi.nlm.nih.gov/42873976/